Welcome to our dedicated page for Cardiol Therapeu news (Ticker: CRDL), a resource for investors and traders seeking the latest updates and insights on Cardiol Therapeu stock.
News about Cardiol Therapeutics Inc. (CRDL) centers on its progress as a clinical-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Headlines frequently highlight updates from the company’s key clinical programs, including the MAVERIC Program in recurrent pericarditis and the ARCHER trial in acute myocarditis, both of which evaluate its lead small-molecule drug candidate, CardiolRx™.
Investors following CRDL news can expect detailed coverage of clinical milestones such as database lock, topline results, and comprehensive data presentations from randomized, double-blind, placebo-controlled trials. Recent releases describe notable improvements in cardiac magnetic resonance imaging measures in acute myocarditis and progress in the pivotal Phase III MAVERIC trial, which focuses on preventing recurrent pericarditis episodes and reducing symptoms like chest pain and inflammation.
Company news also reports on regulatory and strategic developments, including Orphan Drug Designation for CardiolRx™ in pericarditis, Investigational New Drug authorizations, and intellectual property advances. For example, Cardiol has announced a U.S. patent allowance for cannabidiol compositions for treating heart conditions, expected to protect the use of CardiolRx™ and CRD-38 across a range of cardiac disorders into late 2040.
Additional news items cover financings that support the company’s clinical programs and extend its operating runway, as well as participation in scientific and investor conferences where management discusses trial data and development plans. This news page aggregates these updates so readers can monitor Cardiol Therapeutics’ ongoing clinical results, regulatory milestones, financing activities, and pipeline progress in inflammatory heart disease.
Cardiol Therapeutics (NASDAQ: CRDL, TSX: CRDL) has announced that its Annual General and Special Meeting of Shareholders will be held virtually on June 26, 2024, at 4:30 p.m. EDT. The meeting will be accessible via a live audio webcast at web.lumiagm.com/253136217. During this event, shareholders can participate and vote on various matters. Cardiol is a clinical-stage company dedicated to developing anti-inflammatory and anti-fibrotic therapies for heart disease. Further details on the AGM and participation instructions are available on Cardiol's investor website.
Cardiol Therapeutics announced positive topline data from its Phase II MAvERIC-Pilot study, evaluating CardiolRxTM for treating recurrent pericarditis. The 8-week clinical data showed a significant reduction in pericarditis pain and inflammation. The study involved 27 patients, and 89% continued into the extension phase. Notably, 80% of patients with elevated CRP levels at baseline showed normalization. The primary endpoint revealed a mean pain reduction of 3.7 on the NRS scale. CardiolRxTM was well-tolerated and appears promising for future Phase III trials.
Cardiol Therapeutics presented its Phase II ARCHER trial at the World Congress on Acute Heart Failure 2024. The trial is evaluating CardiolRx™ in patients with acute myocarditis. The presentation included the trial design, rationale, and baseline data on the first 50 patients randomized.
The ARCHER trial has exceeded 85% of target enrollment, with a target of 100 patients across multiple countries. Its primary measures are cardiac MRI assessments of left ventricular function and myocardial edema/fibrosis. The MAvERIC-Pilot Phase II study for recurrent pericarditis is expected to report topline results in June 2024.
Acute myocarditis is a severe inflammatory condition with significant health risks. Cardiol's CEO highlighted the growing interest in myocarditis treatments and the contributions of clinical collaborators to the study's progress.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.